NCT00189904View on ClinicalTrials.gov

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

151

Participants

Timeline

Start Date

July 31, 2005

Conditions

HIV Infections

Interventions

BIOLOGICAL

IMVAMUNE (MVA-BN)

Trial Locations (5)

37203

Vanderbilt AIDS Clinical Trials Center, Nashville

46202-2859

Indiana University School of Medicine, Indianapolis

40536-0093

University of Kentucky Medical Center, Lexington

Unknown

Washington University School of Medicine, St Louis

19104-6073

University of Pennsylvania, Philadelphia

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Bavarian Nordic

INDUSTRY